Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Locus Biosciences
AddedFeb 15, 2024
UpdatedJun 18, 2026
Locus Biosciences

Locus Biosciences

Locus Biosciences: A preclinical biotech firm developing precision antibacterial products.

HQ
Morrisville, NC, US
Founded
2015
Overview
Compare
Fundraising
Employees
Website

Locus Biosciences, founded in 2015, is a biotechnology company focused on developing CRISPR-engineered precision antibacterial products. Their core mission is to combat the growing antimicrobial resistance (AMR) pandemic and treat diseases of the microbiome. The company offers innovative precision medicines designed to target specific bacterial infections, leveraging CRISPR technology to enhance the efficacy and specificity of their treatments. Locus Biosciences primarily targets markets affected by high-prevalence bacterial infections, such as urinary tract infections (UTIs).

Notable figures associated with Locus Biosciences include its founders and key investors who have supported its mission. The company has achieved significant milestones, including securing substantial funding from the Biomedical Advanced Research and Development Authority (BARDA) to support the first phase trial of its CRISPR-engineered bacteriophage therapy. Locus Biosciences has made a considerable impact in the field of biotechnology by pioneering advanced solutions to address AMR and microbiome-related diseases, positioning itself as a leader in precision antibacterial therapies.

Locus Biosciences - Quick Facts

When was Locus Biosciences founded?

Locus Biosciences was founded in 2015.

Where is Locus Biosciences' headquarters located?

Locus Biosciences' headquarters is located in Morrisville, NC, US.

When was Locus Biosciences' last funding round?

Locus Biosciences' most recent funding round was for $35M (USD) in May 2022.

How much has Locus Biosciences raised to-date?

As of May 18, 2022, Locus Biosciences has raised a total of $118.7M (USD).

How many employees does Locus Biosciences have?

Locus Biosciences has 80 employees as of Feb 4, 2024.

Locus Biosciences - Classification

Ownership
  • Venture Capital
Technology
  • Biotech
  • Crispr
Geographic Exposure
  • Global
Revenue
  • Licensing
  • Recurring
  • Software
Customer
  • Enterprise
  • Government
Main Product
  • Antibacterial Products
NAICS
  • 620000Health Care and Social Assistance
  • 623000Nursing and Residential Care Facilities
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
Show 16 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 325000Chemical Manufacturing
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 325410Pharmaceutical and Medicine Manufacturing
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 2830Drugs
  • 8730Research, Development, And Testing Services
  • 2834Pharmaceutical Preparations
  • 8731Commercial Physical and Biological Research